Clinical Trial Update: A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous denileukin diftitox plus subcutaneous pegylated interferon-alpha-2a in Stage III/IV ovarian-related cancers; the study was …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• Denileukin diftitox (Ontak) (denileukin diftitox)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2013-07-02